Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: Initial experience

Thomas D. Atwell, Michael A. Farrell, Matthew R Callstrom, J. William Charboneau, Bradley C. Leibovich, David E. Patterson, George K. Chow, Michael L. Blute

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Purpose: To retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT), for the treatment of solid renal masses. Materials and Methods: This study was compliant with the Health Insurance Portability and Accountability Act and had institutional review hoard approval; informed consent was waived. From March 12, 2003, through August 4, 2005, 23 men and 17 women (mean age, 76 years ± 9.7 [standard deviation]; range, 53-92 years), each with a single renal tumor, underwent one percutaneous cryoablation treatment session that combined ultrasonographic (US) guidance and CT monitoring. Technical success was defined as extension of the visible ice ball 5 mm beyond the tumor margin. Local tumor progression was defined as any tumor with intralesional enhancement or a serial increase in tumor size when compared with that on images obtained immediately after ablation. Tumor characteristics, complications, and follow-up were evaluated. Results: The maximum diameter of the 40 treated lesions ranged from 1.5 to 7.2 cm (mean, 3.4 cm ± 1.3). Twenty (50%) of 40 tumors were 3 cm or larger in diameter. Nineteen tumors (48%) extended into the renal sinus fat. One complication (2%) conformed to a grade 3 event, as determined with the Common Terminology Criteria for Adverse Events (version 3.0) of the National Cancer Institute; the overall complication rate was 8%. Thirty-eight (95%) of 40 cryoablation procedures were technically successful. Twenty-nine patients underwent follow-up (mean, 8.0 months ± 4.3 range; range 1.2-18.4 months); no local tumor recurrence was found. Conclusion: Percutaneous cryoablation with US guidance and CT monitoring is safe and effective for the treatment of solid renal tumors. Longer follow-up should provide further proof of the effectiveness of this technique.

Original languageEnglish (US)
Pages (from-to)276-283
Number of pages8
JournalRadiology
Volume243
Issue number1
DOIs
StatePublished - Apr 2007

Fingerprint

Cryosurgery
Tomography
Kidney
Neoplasms
Health Insurance Portability and Accountability Act
National Cancer Institute (U.S.)
Ice
Informed Consent
Terminology
Therapeutics
Fats
Safety
Recurrence

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Atwell, T. D., Farrell, M. A., Callstrom, M. R., Charboneau, J. W., Leibovich, B. C., Patterson, D. E., ... Blute, M. L. (2007). Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: Initial experience. Radiology, 243(1), 276-283. https://doi.org/10.1148/radiol.2431052133

Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring : Initial experience. / Atwell, Thomas D.; Farrell, Michael A.; Callstrom, Matthew R; Charboneau, J. William; Leibovich, Bradley C.; Patterson, David E.; Chow, George K.; Blute, Michael L.

In: Radiology, Vol. 243, No. 1, 04.2007, p. 276-283.

Research output: Contribution to journalArticle

Atwell, TD, Farrell, MA, Callstrom, MR, Charboneau, JW, Leibovich, BC, Patterson, DE, Chow, GK & Blute, ML 2007, 'Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: Initial experience', Radiology, vol. 243, no. 1, pp. 276-283. https://doi.org/10.1148/radiol.2431052133
Atwell, Thomas D. ; Farrell, Michael A. ; Callstrom, Matthew R ; Charboneau, J. William ; Leibovich, Bradley C. ; Patterson, David E. ; Chow, George K. ; Blute, Michael L. / Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring : Initial experience. In: Radiology. 2007 ; Vol. 243, No. 1. pp. 276-283.
@article{e2872463edd5409e955259aaa217a9a2,
title = "Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: Initial experience",
abstract = "Purpose: To retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT), for the treatment of solid renal masses. Materials and Methods: This study was compliant with the Health Insurance Portability and Accountability Act and had institutional review hoard approval; informed consent was waived. From March 12, 2003, through August 4, 2005, 23 men and 17 women (mean age, 76 years ± 9.7 [standard deviation]; range, 53-92 years), each with a single renal tumor, underwent one percutaneous cryoablation treatment session that combined ultrasonographic (US) guidance and CT monitoring. Technical success was defined as extension of the visible ice ball 5 mm beyond the tumor margin. Local tumor progression was defined as any tumor with intralesional enhancement or a serial increase in tumor size when compared with that on images obtained immediately after ablation. Tumor characteristics, complications, and follow-up were evaluated. Results: The maximum diameter of the 40 treated lesions ranged from 1.5 to 7.2 cm (mean, 3.4 cm ± 1.3). Twenty (50{\%}) of 40 tumors were 3 cm or larger in diameter. Nineteen tumors (48{\%}) extended into the renal sinus fat. One complication (2{\%}) conformed to a grade 3 event, as determined with the Common Terminology Criteria for Adverse Events (version 3.0) of the National Cancer Institute; the overall complication rate was 8{\%}. Thirty-eight (95{\%}) of 40 cryoablation procedures were technically successful. Twenty-nine patients underwent follow-up (mean, 8.0 months ± 4.3 range; range 1.2-18.4 months); no local tumor recurrence was found. Conclusion: Percutaneous cryoablation with US guidance and CT monitoring is safe and effective for the treatment of solid renal tumors. Longer follow-up should provide further proof of the effectiveness of this technique.",
author = "Atwell, {Thomas D.} and Farrell, {Michael A.} and Callstrom, {Matthew R} and Charboneau, {J. William} and Leibovich, {Bradley C.} and Patterson, {David E.} and Chow, {George K.} and Blute, {Michael L.}",
year = "2007",
month = "4",
doi = "10.1148/radiol.2431052133",
language = "English (US)",
volume = "243",
pages = "276--283",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring

T2 - Initial experience

AU - Atwell, Thomas D.

AU - Farrell, Michael A.

AU - Callstrom, Matthew R

AU - Charboneau, J. William

AU - Leibovich, Bradley C.

AU - Patterson, David E.

AU - Chow, George K.

AU - Blute, Michael L.

PY - 2007/4

Y1 - 2007/4

N2 - Purpose: To retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT), for the treatment of solid renal masses. Materials and Methods: This study was compliant with the Health Insurance Portability and Accountability Act and had institutional review hoard approval; informed consent was waived. From March 12, 2003, through August 4, 2005, 23 men and 17 women (mean age, 76 years ± 9.7 [standard deviation]; range, 53-92 years), each with a single renal tumor, underwent one percutaneous cryoablation treatment session that combined ultrasonographic (US) guidance and CT monitoring. Technical success was defined as extension of the visible ice ball 5 mm beyond the tumor margin. Local tumor progression was defined as any tumor with intralesional enhancement or a serial increase in tumor size when compared with that on images obtained immediately after ablation. Tumor characteristics, complications, and follow-up were evaluated. Results: The maximum diameter of the 40 treated lesions ranged from 1.5 to 7.2 cm (mean, 3.4 cm ± 1.3). Twenty (50%) of 40 tumors were 3 cm or larger in diameter. Nineteen tumors (48%) extended into the renal sinus fat. One complication (2%) conformed to a grade 3 event, as determined with the Common Terminology Criteria for Adverse Events (version 3.0) of the National Cancer Institute; the overall complication rate was 8%. Thirty-eight (95%) of 40 cryoablation procedures were technically successful. Twenty-nine patients underwent follow-up (mean, 8.0 months ± 4.3 range; range 1.2-18.4 months); no local tumor recurrence was found. Conclusion: Percutaneous cryoablation with US guidance and CT monitoring is safe and effective for the treatment of solid renal tumors. Longer follow-up should provide further proof of the effectiveness of this technique.

AB - Purpose: To retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT), for the treatment of solid renal masses. Materials and Methods: This study was compliant with the Health Insurance Portability and Accountability Act and had institutional review hoard approval; informed consent was waived. From March 12, 2003, through August 4, 2005, 23 men and 17 women (mean age, 76 years ± 9.7 [standard deviation]; range, 53-92 years), each with a single renal tumor, underwent one percutaneous cryoablation treatment session that combined ultrasonographic (US) guidance and CT monitoring. Technical success was defined as extension of the visible ice ball 5 mm beyond the tumor margin. Local tumor progression was defined as any tumor with intralesional enhancement or a serial increase in tumor size when compared with that on images obtained immediately after ablation. Tumor characteristics, complications, and follow-up were evaluated. Results: The maximum diameter of the 40 treated lesions ranged from 1.5 to 7.2 cm (mean, 3.4 cm ± 1.3). Twenty (50%) of 40 tumors were 3 cm or larger in diameter. Nineteen tumors (48%) extended into the renal sinus fat. One complication (2%) conformed to a grade 3 event, as determined with the Common Terminology Criteria for Adverse Events (version 3.0) of the National Cancer Institute; the overall complication rate was 8%. Thirty-eight (95%) of 40 cryoablation procedures were technically successful. Twenty-nine patients underwent follow-up (mean, 8.0 months ± 4.3 range; range 1.2-18.4 months); no local tumor recurrence was found. Conclusion: Percutaneous cryoablation with US guidance and CT monitoring is safe and effective for the treatment of solid renal tumors. Longer follow-up should provide further proof of the effectiveness of this technique.

UR - http://www.scopus.com/inward/record.url?scp=34147210846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147210846&partnerID=8YFLogxK

U2 - 10.1148/radiol.2431052133

DO - 10.1148/radiol.2431052133

M3 - Article

C2 - 17329689

AN - SCOPUS:34147210846

VL - 243

SP - 276

EP - 283

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -